{"organizations": [], "uuid": "9d4d1f359987de84ed858c79322e6cf021b5078a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-hemostemix-signs-license-agreement/brief-hemostemix-signs-license-agreement-with-aspire-health-science-idUSFWN1QD15T", "country": "US", "domain_rank": 408, "title": "BRIEF-Hemostemix Signs License Agreement With Aspire Health Science", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-23T15:04:00.000+02:00", "replies_count": 0, "uuid": "9d4d1f359987de84ed858c79322e6cf021b5078a"}, "author": "", "url": "https://www.reuters.com/article/brief-hemostemix-signs-license-agreement/brief-hemostemix-signs-license-agreement-with-aspire-health-science-idUSFWN1QD15T", "ord_in_thread": 0, "title": "BRIEF-Hemostemix Signs License Agreement With Aspire Health Science", "locations": [], "entities": {"persons": [], "locations": [{"name": "panama", "sentiment": "none"}, {"name": "dominican republic", "sentiment": "none"}, {"name": "costa rica", "sentiment": "none"}, {"name": "mexico", "sentiment": "none"}], "organizations": [{"name": "brief-hemostemix signs license agreement with aspire health science", "sentiment": "negative"}, {"name": "hemostemix inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 05 PM / Updated 13 minutes ago BRIEF-Hemostemix Signs License Agreement With Aspire Health Science Reuters Staff Feb 23 (Reuters) - Hemostemix Inc: * HEMOSTEMIX SIGNS LICENSE AGREEMENT WITH ASPIRE HEALTH SCIENCE * HEMOSTEMIX INC - FINALIZED TERMS OF A LICENSE AGREEMENT WITH ASPIRE FOR CO‘S LEAD THERAPEUTIC PRODUCT TECHNOLOGY, ACP-01 * HEMOSTEMIX INC - LICENSE AGREEMENT HAS INITIAL THREE YEAR TERM, WITH OPTIONS FOR CO TO RENEW FOR ADDITIONAL TWO YEAR EXTENSIONS * HEMOSTEMIX-ASPIRE ‍HAS EXCLUSIVE RIGHTS TO USE, SELL, IMPORT ACP-01 IN THE BAHAMAS, COSTA RICA, DOMINICAN REPUBLIC, MEXICO, PANAMA AND STATE OF FLORIDA​ Source text for Eikon:  ", "external_links": [], "published": "2018-02-23T15:04:00.000+02:00", "crawled": "2018-02-23T15:24:40.010+02:00", "highlightTitle": ""}